

Australia's Cell Therapies partners with Teijin to expand access to advanced cell and gene therapies in Japan and APAC region

01 October 2025 | News

To combine Cell Therapies' long-standing expertise with Teijin's strong manufacturing capabilities



Australia-based Cell Therapies and Japan's Teijin Limited have signed a Memorandum of Understanding (MoU) to strengthen regional infrastructure for cell and gene therapies (CGT), leveraging advanced GMP capabilities and cross-border collaboration to accelerate development and improve patient access across Japan and the wider Asia Pacific region.

This partnership will combine Cell Therapies' long-standing expertise as Australia's leading CGT CDMO with Teijin's strong manufacturing capabilities in CGT and regenerative medicine via their group companies Teijin Regenet Co. and Japan Tissue Engineering Co. (J-TEC) in Japan.

The collaboration aims to streamline access to regional markets by enabling cross-border clinical trial and commercial supply, knowledge exchange, and regulatory alignment to support innovative CGT programs.

Through this collaboration, the companies intend to:

- Expand regional GMP manufacturing capacity for cell and gene therapies (CGT)
- Enable efficient technology transfer and multi-site delivery across APAC
- Facilitate clinical trial and market access for advanced therapies in Japan and Australia
- Build long-term infrastructure and capability through joint training and workforce development initiatives